--- title: "AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus" type: "News" locale: "en" url: "https://longbridge.com/en/news/294722299.md" description: "AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a potential $400 billion merger, which would create the world's fourth-largest drugmaker. Analysts highlight significant valuation benchmarks, patent expiration risks by 2030 affecting $50 billion in revenue, and intense regulatory scrutiny as key factors shaping the deal's outcome." datetime: "2026-08-03T17:13:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294722299.md) - [en](https://longbridge.com/en/news/294722299.md) - [zh-HK](https://longbridge.com/zh-HK/news/294722299.md) --- # AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus As per a media report over the weekend, **AstraZeneca Plc** (NYSE:AZN) and **Bristol Myers Squibb Co**. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion. The news took the healthcare sector by storm, and the merger would position AstraZeneca as the world’s fourth-largest drugmaker by market capitalization. ## Prior Pharma Deals For Valuation Benchmarks AstraZeneca’s market value stands at approximately $263 billion, while Bristol Myers Squibb is valued at around $133 billion, according to Benzinga Pro data. **William Blair** on Monday wrote, “Given the size of the two companies, we assume the deal would be largely stock-based, which could result in Bristol Myers shareholders holding roughly one-third of the combined company based on today’s market caps.” Assuming 4 times William Blair’s 2028 revenue estimate of $39.5 billion for Bristol Myers would suggest a take-out value of roughly $160 billion. **Read Also: Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review** Analyst Matt Phipps notes the Celgene acquisition by Bristol Myers, the Allergan acquisition by **AbbVie Inc.** (NYSE:ABBV), and the Wyeth acquisition by **Pfizer Inc.** (NYSE:PFE) could serve as useful comps for revenue multiples, with a range of 3.5x to 4.5x one-year forward consensus revenues. The impending loss of exclusivity for Bristol Myers’ Eliquis in April 2028 would likely weigh negatively on the forward multiple ahead of additional clinical readouts with milvexian. ## Patent Expirations And Regulatory Review Could Shape Deal Outcome Analyst Phipps said both companies face significant patent expirations by 2030, affecting key brands that generated about $50 billion in combined 2025 revenue. He said that would increase the importance of operational synergies to justify any merger. Phipps also said a deal of this scale would likely face intense regulatory scrutiny, particularly in the U.K., where AstraZeneca is a key player in the country’s biopharma research and development ecosystem. Overall, he noted that Bristol Myers is entering a challenging period as revenue declines from patent expirations accelerate, while smaller acquisitions may not be enough to offset losses from legacy products. A large strategic merger could create near-term shareholder value, though he said it is too early to assess the merits of a potential AstraZeneca deal without details on the transaction terms. **AZN/BMY Stock Price Activity**: AstraZeneca shares were down 7.98% at $156.10 at the time of publication on Monday, and Bristol-Myers Squibb shares were down 0.90% at $64.72 at the time of publication on Monday, according to Benzinga Pro data. **Read Also: Insurance Stumbles, But Loews Still Delivers Higher Profit Thanks to Hotels and Energy** _Image via Shutterstock_ ### Related Stocks - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [TERN.US](https://longbridge.com/en/quote/TERN.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [L.US](https://longbridge.com/en/quote/L.US.md) - [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md) ## Related News & Research - [An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'](https://longbridge.com/en/news/294738560.md) - [Why Is Bristol-Myers Squibb Stock Surging Monday?](https://longbridge.com/en/news/294697898.md) - [Investors Buy Large Volume of Call Options on Astrazeneca (NYSE:AZN)](https://longbridge.com/en/news/294716282.md) - [$400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"](https://longbridge.com/en/news/294687964.md) - [Key facts: AstraZeneca (AZN) merger talks with BMS; 6% revenue rise](https://longbridge.com/en/news/294654032.md)